logo-loader

ChemioCare USA Inc rebrands itself as Starton Therapeutics as it hones it on bigger opportunities

Published: 15:49 30 Dec 2019 EST

ChemioCare - ChemioCare USA Inc rebrands itself as Starton Therapeutics as it hones it on bigger opportunities
 At the core of the privately-held company's business is its transdermal technology which uses adhesive patches to deliver generic medicines via the skin

ChemioCare USA Inc announced that it has changed the name of the company to Starton Therapeutics Inc to reflect its evolution from a cancer supportive care company to a company with the potential to address "a wide range of therapeutic areas," including hematology and cancer therapeutics beyond chemotherapy.

In a statement, the privately-held company said last week that it expects to launch its new corporate website in early January 2020.

The company develops transdermal delivery treatments, or the administering of medicine via patches placed on the skin. It currently has three patches in development for cancer and palliative care and expects to enter Phase 3 pivotal studies later this year.

READ: ChemioCare taps retired Pfizer exec to its board

CEO Pedro Lichtinger who is also the chairman threw more light on the company's new identity.

“In talking with physicians, payers, and the scientific community we have identified numerous breakthrough applications for our patch technology to improve patient outcomes and address significant unmet medical needs,” said Lichtinger.

“With the many opportunities we continue to uncover for transdermal delivery, we knew we had outgrown our “Chemio” moniker. This rebranding transpires subsequent to the achievement of two substantial development milestones for the company. The completion of our olanzapine patch human bioavailability study and lenalidomide myeloma model study in late 2019 signal a new direction for Starton.”

At the core of Starton Therapeutics business, which is roughly two years old, is its transdermal technology, which uses adhesive patches to deliver generic medicines via the skin.

Unlike patches that must be replaced every six to eight hours, ChemioCare’s products release drugs in a controlled and sustained way over the course of five to seven days. 

Contact the author Uttara Choudhury at uttara@proactiveinvestors.com

Follow her on Twitter: @UttaraProactive 

ARway.ai announces multiple new SaaS developer contracts in both the United...

ARway.ai (CSE:ARWY, OTCQB:ARWYF) Chief Executive Officer Evan Gappelberg joined Steve Darling from Proactive to announce multiple new SaaS developer sign-ups for its augmented reality experience platform, focusing on AR indoor navigation. These partnerships represent significant milestones in...

1 hour, 46 minutes ago